Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cancer Cell. 2022 Mar 14;40(3):252-254. doi: 10.1016/j.ccell.2022.02.017.
In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.
在最近的《柳叶刀肿瘤学》杂志的一篇文章中，Yau 等人报告了 CheckMate 459 试验的结果。这是首个比较单药抗程序性死亡蛋白 1（PD-1）治疗药物纳武利尤单抗与酪氨酸激酶抑制剂索拉非尼治疗初治晚期肝细胞癌患者的 III 期临床试验。
